A Phase 1/2 Study of IDP-121 in Patients With Relapsed/Refractory Hematologic Malignancies
Status:
Recruiting
Trial end date:
2025-06-02
Target enrollment:
Participant gender:
Summary
The main aims of this 2-part study are:
- Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose
(RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma
not otherwise specified (DLBCL-NOS), high-grade B cell lymphoma with double or triple
hit rearrangement (HGBL-DH/TH) and HGBL-NOS, and chronic lymphocytic leukemia (CLL).
- Phase II: To evaluate the overall response rate (ORR) in patients with MM, DLBCL-NOS,
HGBL-DH/TH, HGBL-NOS or CLL treated with IDP-121 at the recommended Phase 2 Dose (RP2D).